^
Association details:
| Biomarker: | PIK3CA mutation + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) + Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Published date:
08/14/2020
Excerpt:
Follow-up analysis, monitoring xenograft regrowth post-withdrawal of treatment, identified significantly less xenograft regrowth in the mice treated with the triplet combination of alpelisib/ribociclib/fulvestrant compared to the singlet and doublet treatment arms (Fig. 5d).
Secondary therapy:
fulvestrant
DOI:
10.1186/s13058-020-01320-8
